Zacks Investment Research on MSN
IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y
Iovance Biotherapeutics IOVA incurred a third-quarter 2025 loss of 25 cents per share, narrower than the Zacks Consensus Estimate of a loss of 29 cents. In the year-ago quarter, the company reported a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback